Development of Next Generation CNS Drugs: Trontinemab, an Anti-Amyloid Beta Brainshuttle Antibody

Time: 3:15 pm
day: Conference Day Two


  • Developing “Brainshuttle”, a versatile platform to enhance brain delivery of therapeutic proteins and other cargos across the blood brain barrier via receptor mediated transcytosis
  • Showcasing translational strategies and learnings from the Brainshuttle antibody fusion trontinemab: The journey from mice to patients, towards a new generation of Amyloid beta lowering therapies